COVID-19 vaccines for kids under 5: What's coming next?
Pfizer has asked the FDA to authorize extra-low doses of its COVID-19 vaccine for children ages 6 months through 4 years
Former FDA Commissioner Dr. Stephen Hahn argues despite the omicron being more ‘transmissible’ than other variants, it’s ‘encouraging’ to see the COVID-19 booster protect against the disease.
Parents who thought their children under 5 would have to wait several more months for COVID-19 vaccinations instead just might get them as early as March. Here’s what needs to happen first, and some things to expect if they do become available in the U.S.
GOVERNMENT REVIEW
Pfizer has asked the Food and Drug Administration to authorize extra-low doses of its COVID-19 vaccine for children ages 6 months through 4 years. The FDA will review the application and convene a panel of outside advisers in mid-February to debate the data. The FDA will use that advice in deciding whether the new doses are safe and effective enough for the youngest children.
CVS REMOVES COVID-19 TEST PURCHASING LIMITS
But that’s not the last step. The Centers for Disease Control and Prevention will gather its own expert panel to help decide if the shots should be recommended for this age group — and if so, for all of them or only those at higher risk from COVID-19.
A healthcare worker prepares a dose of the Pfizer-BioNTech Covid-19 vaccine at an Oklahoma County Health Department Vaccine Clinic in Oklahoma City, Oklahoma, U.S., on Wednesday, Nov. 17, 2021. (Nick Oxford/Bloomberg via Getty Images)
SPECIAL SHOTS
Shots for children in this age group are one-tenth the size of the adult doses. That’s even smaller than the doses given for 5- to 11-year-olds, which are one-third the dose. Pfizer will have to specially bottle the extra-low doses so vaccine providers don’t mix them up with the two other dosages already being used.
TWO DOSES OR THREE?
Here’s where this gets complicated. In December, Pfizer announced a setback: Preliminary study results showed two of the extra-low doses appeared strong enough to protect babies but weren’t strong enough for 2- to 4-year-olds. The company added a third shot to the study, but results are not expected until late March.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| PFE | PFIZER INC. | 25.76 | -0.41 | -1.55% |
CLICK HERE TO READ MORE ON FOX BUSINESS
Still, the FDA took the highly unusual step of urging Pfizer to apply now for a two-dose series with potentially a third shot added later. During the FDA advisory committee meeting, the public will get its first look at any new evidence of whether two extra-low doses are working better than initially expected among the preschoolers.
IF CLEARED, WHERE WOULD SHOTS BE GIVEN?
While the government expanded pharmacists’ ability to vaccinate children during the pandemic, shots for the youngest children primarily are given in pediatricians’ offices.
Steve Rusckowski discusses how the omicron variant impacted Q4 earnings on 'The Claman Countdown.'
WHAT ABOUT KIDS YOUNGER THAN 6 MONTHS?
There are no plans to test shots in newborns.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
WILL THE SHOTS BE IN HIGH DEMAND?
Vaccinations have been lower among children than in other age groups, a pattern likely to continue with kids under 5. As of last week, just 20% of kids ages 5 to 11 and just over half of 12- to 17-year-olds were fully vaccinated, according to the American Academy of Pediatrics. Nearly three-quarters of adults are fully vaccinated. While COVID-19 tends to be less severe in children than adults, the omicron wave has caused record numbers of child hospitalizations.